Home Stock

Stock Research: Kissei Pharmaceutical

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Kissei Pharmaceutical

TYO:4547 JP3240600001
53
  • Value
    90
  • Growth
    22
  • Safety
    Safety
    42
  • Combined
    47
  • Sentiment
    45
  • 360° View
    360° View
    53
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

KISSEI PHARMACEUTICAL CO.,LTD. is a Japan-based company primarily engaged in the manufacture and sale of pharmaceutical products. Its main businesses include the collection and analysis of medicine development information, manufacture and sale of medicines, purchase and sale of related materials, system development, construction contract work, facility management, and insurance agency business. It primarily operates in Japan. In the last fiscal year, the company had 1778 employees, a market cap of $1308 million, profits of $294 million, and revenue of $589 million.

more

ANALYSIS: With an Obermatt 360° View of 53 (better than 53% compared with alternatives), overall professional sentiment and financial characteristics for the stock Kissei Pharmaceutical are above average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Kissei Pharmaceutical. Only the consolidated Value Rank has an attractive rank of 90, which means that the share price of Kissei Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 90% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 22, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 42, meaning the company has a riskier financing structure than 58% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 55% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 45. ...read more

more
Strongest Rank Liquidity
Weakest Rank Leverage
Country Japan
Industry Pharmaceuticals
Size Medium
Website kissei.co.jp
Index
Kissei Pharmaceutical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
90 76 86 85
Growth
22 51 35 19
Safety
Safety
42 92 65 94
Sentiment
45 32 10 44
360° View
360° View
53 81 45 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
34 17 35 78
Opinions Change
50 28 6 96
Pro Holdings
n/a 80 44 12
Market Pulse
13 44 7 3
Sentiment
45 32 10 44
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
90 76 86 85
Growth
22 51 35 19
Safety Safety
42 92 65 94
Combined
47 98 77 78
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
42 48 55 72
Price vs. Earnings (P/E)
68 56 86 47
Price vs. Book (P/B)
87 95 78 100
Dividend Yield
87 63 78 88
Value
90 76 86 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
27 11 33 67
Profit Growth
40 32 42 11
Capital Growth
9 82 7 1
Stock Returns
63 78 87 71
Growth
22 51 35 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
95 91 85 82
Refinancing
44 83 89 91
Liquidity
4 76 4 61
Safety Safety
42 92 65 94

Similar Stocks

Discover high‑ranked alternatives to Kissei Pharmaceutical and broaden your portfolio horizons.

Inpex

TYO:1605
Country: Japan
Industry: Oil & Gas Production
Size: X-Large
Full Stock Analysis

Daiwa House

TYO:1925
Country: Japan
Industry: Electric Utilities
Size: XX-Large
Full Stock Analysis

NGK Insulators

TYO:5333
Country: Japan
Industry: Industrial Machinery
Size: X-Large
Full Stock Analysis

Kinden

TYO:1944
Country: Japan
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The only strength is good value. All other factors (growth, safety, and sentiment) are below average. This stock is highly sensitive to a crisis and is not advisable. Avoid unless you have solid, independent reasons to believe a significant turnaround is imminent.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews